Becton Dickinson & Co (BDX) Stock Price & Analysis
Becton Dickinson & Co (BDX) rose 2.22% to USD 156.36 as of July 25, 2026 at 06:14 UTC, according to Nexqual real-time market data.
BDX last closed at USD 152.97; the session ranged USD 153.32–156.78 on volume of 1,109,516 shares. Market capitalization is —, with a 52-week range of USD 127.59–187.35 (NYQ). Source: Nexqual, July 25, 2026 at 06:14 UTC.
Key Statistics (as of July 25, 2026 at 06:14 UTC)
| Price | USD 156.36 |
|---|---|
| Change | ▲ 2.22% (up) |
| Previous Close | USD 152.97 |
| Open | USD 154.48 |
| Day Range | USD 153.32 – 156.78 |
| 52-Week Range | USD 127.59 – 187.35 |
| Volume | 1,109,516 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (BDX)
Nexqual's technical model rates BDX "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 06:14 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.31 (neutral) |
| vs SMA50 | Above (USD 149.58) |
| MACD | 1.47 (positive) |
Analyst Ratings (BDX)
Wall Street analysts rate BDX "Buy" based on 11 analysts, with a mean price target of USD 179.36 (range USD 161–225), per Nexqual as of July 25, 2026 at 06:14 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 179.36 |
| High Target | USD 225 |
| Low Target | USD 161 |
| Buy / Hold / Sell | 6 / 7 / 0 |
Earnings (BDX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 3.14 |
| Revenue Estimate | $4.89B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.9 vs est 2.77 ▲ beat |
| 2025-12-31 | USD 2.91 vs est 2.8 ▲ beat |
| 2025-09-30 | USD 3.96 vs est 3.91 ▲ beat |
| 2025-06-30 | USD 3.68 vs est 3.4 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:14 UTC.
Financials & Fundamentals (BDX)
| Total Revenue | $22.23B |
|---|---|
| Revenue Growth (YoY) | +5.20% |
| Gross Margin | +47.09% |
| Operating Margin | +14.74% |
| Profit Margin | +5.12% |
| ROE | +6.67% |
| Debt / Equity | 71.6 |
| Current Ratio | 0.94 |
| Total Cash | $816.00M |
| Total Debt | $17.28B |
| Free Cash Flow | $4.53B |
Source: Nexqual, July 25, 2026 at 06:14 UTC.
Financial Health Score (BDX)
Nexqual rates Becton Dickinson & Co's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 06:14 UTC.
| Growth | Solid — Revenue +5% YoY (latest Q) |
|---|---|
| Profitability | Strong — Gross margin 47%, operating 15% |
| Balance Sheet | Mixed — $816M cash vs $17.3B debt |
| Cash Flow | Strong — FCF $4.53B, 20% margin |
| Efficiency | Mixed — ROE 7%, ROA 4.4% |
Ownership (BDX)
| Insider Ownership | +0.42% |
|---|---|
| Institutional Ownership | +99.21% |
| Float | 274.69M |
| Short % of Float | +4.29% |
Source: Nexqual, July 25, 2026 at 06:14 UTC.
Leadership (BDX)
Becton Dickinson & Co is led by Thomas E. Polen (age 52), President, CEO & Chairman, per Nexqual as of July 25, 2026 at 06:14 UTC.
| President, CEO & Chairman | Thomas E. Polen (age 52) |
|---|---|
| Executive VP & President of Medical Segment and BioPharma Systems Segments | Michael Garrison (age 56) |
| Executive VP & Chief Revenue Officer | Michael C. Feld (age 44) |
| Executive VP & CFO | Vitor Roque (age 42) |
| Executive VP & CTO | Elizabeth McCombs (age 48) |
Major Backers & Investors (BDX)
Notable institutional backers of Becton Dickinson & Co include First Eagle Investment Management, LLC, T. Rowe Price, Invesco, according to Nexqual as of July 25, 2026 at 06:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Eagle Investment Management, LLC | 7.25% |
| T. Rowe Price | 5.62% |
| Invesco | 3.69% |
| Massachusetts Financial Services Co. | 3.3% |
| Wellington Management | 2.4% |
| Fidelity | 1.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.49% |
| BlackRock | 10.85% |
| State Street | 6.23% |
| Geode Capital | 2.58% |
Source: Nexqual, July 25, 2026 at 06:14 UTC.
From Becton Dickinson & Co's Latest SEC 10-K Filing (filed 2025-11-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
- It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
- It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products.
- The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BAX | Baxter International Inc. | USD 22.4 | ▲ 3.04% |
| APD | Air Products and Chemicals, Inc | USD 297.87 | ▲ 0.29% |
| CAH | Cardinal Health, Inc. | USD 228.03 | ▲ 3.4% |
| DOV | Dover Corporation | USD 202.2 | ▼ 5.75% |
| ITW | Illinois Tool Works Inc. | USD 283.02 | ▲ 3.32% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:14 UTC. This page is informational and not investment advice.